Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical characteristics of H1RA responders and H1RA non-responders among CSU patients

From: Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study

Characteristics H1RA responders (n = 169) H1RA non-responders (n = 113) p value
Age (years) 42.3 ± 12.0 42.6 ± 11.4 0.665
Female n (%) 111 (65.7) 73 (64.6) 0.852
BMI (Kg/m2) 23.4 ± 4.1 23.6 ± 3.6 0.577
Urticaria duration (months) 28.8 ± 56.8 22.1 ± 43.0 0.289
UAS7 (0–42) 24.4 ± 10.3 28.8 ± 9.3 < 0.001
Log[Total IgE (kU/L)] 2.07 ± 0.5 2.13 ± 0.5 0.414
ECP (kU/L) 20.8 ± 16.5 23.1 ± 22.4 0.956
Total cholesterol (mg/dL) 194.8 ± 37.1 195.5 ± 36.3 0.985
Triglycerides (ng/dL) 148.7 ± 108.3 153.5 ± 84.8 0.288
LDL (mg/dL) 113.0 ± 37.8 110.7 ± 31.2 0.909
HDL (mg/dL) 56.1 ± 14.8 55.5 ± 15.3 0.862
Platelet (*1000/μL) 262.8 ± 56.7 263.0 ± 56.3 0.654
Mean platelet volume 8.0 ± 0.8 8.0 ± 0.7 0.544
Complement 3 (mg/dL) 108.6 ± 17.6 112.2 ± 24.7 0.525
Complement 4 (mg/dL) 26.3 ± 7.4 27.0 ± 8.6 0.481
H1RA dosea (mg/day) 21.0 ± 9.4 30.8 ± 13.3 < 0.001
Steroid use (%) 88 (52.1) 106 (93.8) < 0.001
Cyclosporine use (%) 0 35 (31.0) < 0.001
Omalizumab use (%) 0 38 (33.6) < 0.001
PAF (pg/ml) 3804.6 [17.0–11716.4] 5426.4 [53.2–14768.3] < 0.001
PAF-AH (ng/ml) 104.2 [2.6–296.5] 112.1 [4.4–256.9] 0.051
  1. p values were obtained by Pearson’s Chi square test for categorical variables and Mann–Whitney U-test for continuous variables
  2. Medication score, daily mean loratadine dose to control symptoms
  3. H1RA histamine receptor 1 antagonist, CSU chronic spontaneous urticaria, BMI body mass index, UAS7 sum of daily urticaria activity scores during the last week, ASST autologous serum skin test, ANA anti-nuclear antibody, ECP eosinophilic cationic protein, LDL low density lipoprotein, HDL high density lipoprotein, PAF platelet activating factor, PAF-AH platelet activating factor acetylhydrolase
  4. aH1RA dose is presented as the mean daily H1RA prescription calculated as the loratadine equivalent dose for 3 months